New drugs list

Here is a list of new drugs that have been approved by regulatory agencies in recent years:

2022

  1. Paxlovid (nirmatrelvir and ritonavir): an oral antiviral medication for the treatment of mild to moderate COVID-19 in adults and children.
  2. Veklury (remdesivir): an intravenous antiviral medication for the treatment of severe COVID-19 in hospitalized adults.
  3. Zynquista (sotagliflozin): an oral medication for the treatment of type 1 diabetes.
  4. Tazverik (tazemetostat): an oral medication for the treatment of follicular lymphoma and other types of non-Hodgkin lymphoma.
  5. Brexafemme (brexanolone): an intravenous medication for the treatment of postpartum depression.

2021

  1. Aduhelm (aducanumab): an intravenous medication for the treatment of Alzheimer's disease.
  2. Vonjo (pacritinib): an oral medication for the treatment of myelofibrosis.
  3. Zepzelca (nelipepimut-S): an oral medication for the treatment of small cell lung cancer.
  4. Imjudo (baricitinib): an oral medication for the treatment of rheumatoid arthritis.
  5. Pralsetinib (Gavreto): an oral medication for the treatment of non-small cell lung cancer.

2020

  1. Veklury (remdesivir): an intravenous antiviral medication for the treatment of severe COVID-19 in hospitalized adults.
  2. Bamlanivimab (LY-CoV555): an intravenous medication for the treatment of mild to moderate COVID-19 in adults.
  3. Eteplirsen (Exondys 51): an oral medication for the treatment of Duchenne muscular dystrophy.
  4. Ozanimod (Zeposia): an oral medication for the treatment of multiple sclerosis.
  5. Risdiplam (Evrysdi): an oral medication for the treatment of spinal muscular atrophy.

2019

  1. Brexafemme (brexanolone): an intravenous medication for the treatment of postpartum depression.
  2. Zynquista (sotagliflozin): an oral medication for the treatment of type 1 diabetes.
  3. Tazverik (tazemetostat): an oral medication for the treatment of follicular lymphoma and other types of non-Hodgkin lymphoma.
  4. Pomalyst (pomalidomide): an oral medication for the treatment of multiple myeloma.
  5. Lutetium Lu 177 dotatate (Lutathera): an injectable medication for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Please note that this is not an exhaustive list, and there may be other new drugs approved by regulatory agencies that are not included here. Additionally, the list only includes drugs that have been approved for use in the United States and may not include drugs approved for use in other countries.